Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 370 participants.
Also called NCT03713684
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 370 participants
- Registry
-
NCT03713684
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, China, South Korea
- Registry status
- Terminated
Technical summary
Registry record NCT03713684. Randomized; quadruple masking; primary purpose treatment. Start 2018-11-09 (actual); primary completion 2020-11-20 (actual). Results posted on 2021-12-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
- Acronym
- AMPLITUDE-L
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Efpeglenatide SAR439977
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Background therapy
- Lead sponsor
- Sanofi
- Collaborator
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct03713684- Content hash
e1e8dcc71474ac5360306616bc923f80af9338c4ebb05be059133a02a7c70090